Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Atopic Dermatitis
Interventions: BTX 1204, Vehicle; Drug
Lead sponsor: Botanix Pharmaceuticals; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Encino, California • Fremont, California + 16 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions: OraVescent Fentanyl; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 38
States / cities: Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Safety Issues, Chronic Kidney Diseases
Interventions: Sick-Day Protocol, Usual Care; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Not listed
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Coagulation Disorders, Inherited, Thrombotic Disorder
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 98 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA, Rosuvastatin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Technetium Tc 99m EC20; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions: Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination); Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sensorineural Hearing Loss, Hearing Loss
Interventions: P300 Visually evoked potential; Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Alzheimer Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Colton, California • San Diego, California • Atlantis, Florida + 16 more

Conditions: Acromegaly
Interventions: Paltusotine; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Atrophic Acne Scar
Interventions: Normal Saline, Artefill; Drug · Device
Lead sponsor: Suneva Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more

Conditions: Atrial Fibrillation
Interventions: Esophageal warming device (Attune Medical, Chicago, IL; Device
Lead sponsor: Advanced Cooling Therapy, Inc., d/b/a Attune Medical; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winchester, Virginia

Conditions: Diabetes, Cerebrovascular Disease, Age-Associated Decline, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 30 Years to 64 Years
Enrollment: 3,720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis
Interventions: High molecular weight hylan (Synvisc) injection; Procedure
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV/AIDS, Young Adult, Mobile Health, Mental Health Issue, Substance Use
Interventions: Standard of Care, Video-counseling+app; Other · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 29 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Breast Cancer, End of Life
Interventions: Clinician Qualitative Interview; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Deafness, Hearing Loss
Interventions: cochlear implantation, hearing aids; Device
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 5 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Stanford, California • Houston, Texas

Conditions: Polycythemia Vera
Interventions: XL019; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 2 more

Conditions: Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Sedation, Sleep
Interventions: Continuous bedside video monitoring with AI anatomic landmark tracking for neurologic monitoring; Device
Lead sponsor: Artemis AI Labs; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York

Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Interventions: frexalimab, brivekimig, rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 15 more

Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, MTBI - Mild Traumatic Brain Injury, Closed Head Injury
Interventions: EEG Recording, Neurocognitive Tests, Clinician Evaluation, 22-item CSI; Device · Other
Lead sponsor: BrainScope Company, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Detroit, Michigan • Royal Oak, Michigan • Troy, Michigan + 2 more

Conditions: Colon Cancer
Interventions: Straw; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease

Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Quantification of Visually Evoked Cortical Potentials in Individuals With Hearing Loss

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures

Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)

Synvisc to Treat Osteoarthritis of the Temporomandibular Joint

Intervention for Virologic Suppression in Youth

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

Outcomes In Children With Developmental Delay And Deafness

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Neonatal Neurological Observation With Video AI

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Follow-up of MTBI Patients Discharged from the ED Using Standard Clinical Triage Including BrainScope One

Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation